It first attained FDA approval in 2018 in clinically advanced ALK-altered NSCLC patients that had progressed on first- and second-generation ALK inhibitors such crizotinib/ceritinib/alectinib based on results of a phase II study112. The gene discussed is ALK; the disease is non-small cell lung carcinoma.